重组人脑利钠肽对急性心力衰竭患者心功能和炎症介质的影响

目的：评价重组人脑利钠肽（rhBNP）治疗急性心力衰竭（AHF）患者对心功能及炎症因子的影响。方法：90例AHF患者被随机分为常规治疗组（45例）及rhBNP组（45例，在常规治疗基础上静脉注射rhBNP，共3d）。比较两组治疗前后左室射血分数（LVEF），炎症介质：血清高敏c反应蛋白（hsCRP）、白细胞介素-6（IL-6）等水平的变化。结果：治疗后与常规治疗组比较，rhBNP组LVEF[（42．7±13．1）％比（50．9±14．5）％]显著提高，心率[（85．7±17．7）次／min比（73．5±16．1）次／min]、脑利钠肽[（1142．6±287．5）ng／L比（976．7±235．7）ng／L]、hsCRP[（8．45±2．68）mg／L比（6．82±2．57）mg／L]、IL-6[（16．07±4．75）pg／L比（13．35±4．18）pg／L]水平显著降低（P均〈0．05）。结论：重组人脑利钠肽治疗急性心力衰竭效果显著，可改善患者预后。

Influence of rhBNP on cardiac function and modiator of inflammation in patients with acute heart fail-ure

Objective： To evaluate clinical therapeutic effects of recombinant human brain natriuretic peptide （rhB-NP, Xinhuosu） on cardiac function and modiator of inflammation in patients with acute heart failure （AHF）. Meth-ods： A total of 90 AHF patients were randomly divided into routine treatment group （n = 45） and rhBNP group （n = 45, received intravenous injection of rhBNP for 3d based on routine treatment）. Levels of LVEF and mediator of inflammation： serum hsCRP, interleukin-6 （IL- 6） were compared between two groups before and after treat-ment. Results： Compared with routine treatment group after treatment, there was significant increase in LVEF [ （42.7± 13.1） % vs. （50.9 ± 14.5） %], significant decrease in heart rate [ （85.7 ± 17.7） times/min vs. （73.5 ±16.1） times/mini, levels of brain natriuretic peptide [BNP, hsCRPE （8.45±2.68） mg/Lvs. （6.82±2.57） mg/L] andlL （1142.6± 287.5） ng/L vs. （976.7 ± 235.7） ng/L], -6[ （16.07±4.75） pg/Lvs. （13.35±4.18） pg/L] in rhBNP group, P〈0.05 all. Conclusion.. The rhBNP possesses significant effect on cardiac function and mediator of inflammation in AHF patients.